Claris Lifesciences listed at Rs 224.40 today on Bombay Stock Exchange as against its issue price of Rs 228 per share, below 1.6 per cent. The scrip touched its intra-day high of Rs 227.90 and low level of Rs 200. The scrip eventually closed at Rs 216.30 in the last session.



Claris, one of the largest Indian sterile injectables pharmaceutical companies with a presence in 76 countries worldwide, concluded public offer aggregating to Rs.300 crore comprising equity shares of Rs.10 each through a 100% Book Building Process. The Issue was closed on December 2, 2010.



The company’s products offering comprise 128 products across multiple markets and therapeutic areas. All of their products are off-patent products, a significant majority of which are capable of being directly injected into the body and are predominantly used in the treatment of critical illnesses.



Its products range across various therapeutic segments, including anesthesia, critical care, anti-infectives, renal care, infusion therapy, enteral nutrition, parenteral nutrition and oncology. The company offers injectables in various delivery systems, such as glass and plastic bottles, vials, ampoules, pre-filled syringes and non-PVC and PVC bags. The customer base primarily includes government and private hospitals, aid agencies and nursing homes.



One of the company’s key products, propofol, represented approximately 14.84% of their total sales for the financial year ended December 31, 2009 and for the five month period ended May 31, 2010 represented approximately 12.52% of the total sales in that period. Claris holds patents for APIs for their hydroxyl ethyl starch product. Its regulatory team has developed capabilities and processes to file product registrations in regulated and emerging markets; as of September 30, 2010, they had obtained over 1,100 registrations worldwide and approximately 324 applications were pending approval.